id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-326010-8f891ocp	Wang, Yibin	Using “old” medications to fight new COVID-19: Re-purposing with a purpose	2020-07-18		.txt	text/plain	754	36	39	Despite the unprecedented efforts and rapid scientific progress in the discovery of the cellular and molecular details for the pathogenesis of COVID-19 as a result of SARS-COV2 infection, there are still no specific new therapies that have been approved to either prevent or treat COVID19 in clinics [1, 2] . In recent retrospective studies led by a consortium of investigators based on a large clinical cohort of hospitalized COVID-19 patients in Hubei, China, one class of medicine originally used for blood pressure management (angiotensin-converting enzyme inhibitor or angiotensin-receptor blockers) [7] , and another class of medication originally prescribed for hyperlipidemia (statins) [8] , were analyzed for their association with COVID-19 related death and other secondary outcome. After extensive adjustment and matching for major clinical risk profiles, statistical analyses showed both ACEi/ARB and statins were found to be associated with a significant reduction in death and adverse outcome in hospitalized COVID-19 patients. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19	./cache/cord-326010-8f891ocp.txt	./txt/cord-326010-8f891ocp.txt